Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
Imalumab is a monoclonal antibody binds to and inhibits macrophage migration inhibitory factor (MIF) signaling therefore inhibits tumor cell proliferation (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Imalumab||BAX-69|BAX069|BAX69||Imalumab (BAX069) is a monoclonal antibody that binds to macrophage migration inhibitory factor (MIF), which may lead to inhibition of the MAPK and PI3K/mTOR/Akt pathways, and subsequent tumor cell proliferation (PMID: 32207164).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Imalumab||Phase I||Actionable||In a Phase I trial, treatment with Imalumab (BAX069) demonstrated safety and tolerability, and resulted in a best overall response of stable disease in 26% (13/50) of patients with an advanced solid tumor, with 8 patients achieving stable disease for 4 months or longer (PMID: 32207164; NCT01765790).||32207164|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02540356||Phase Ib/II||Imalumab||Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer||Terminated|
|NCT02448810||Phase II||Fluorouracil + Leucovorin Imalumab Panitumumab||Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer||Terminated|